Eversense®
CGM System
The world's FIRST and ONLY long-term Continuous Glucose Monitoring System
Tim Goodnow, PhD | Corporate Presentation |
President and CEO | August 2022 |
1
FORWARD-LOOKINGSTATEMENTS
Any statements in this presentation about future expectations, plans and prospects for Senseonics, including statements about patient benefits, perceptions, uptake of the Eversense E3 product, and the ability to introduce the product to additional patients, statements regarding future coverage decisions and final outcomes, statements concerning Senseonics' product pipeline and future product enhancements, and other statements containing the words "believe,""expect," "anticipate", "intend," "may," "projects," "will," "planned," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of
1995. These forward-looking statements are based on management's current expectations and projections about future events, and such statements are, by their nature
subject to uncertainties.
The risks and uncertainties that may cause actual results, levels of activity, performance or achievements to differ materially from the Company's current expectations include uncertainties related to the commercial launch and commercial expansion of the Eversense product, uncertainties inherent in the transition of commercialization responsibilities to Ascensia Diabetes Care and its commercial initiatives, uncertainties in insurer, regulatory and administrative processes, decisions and policy
determinations, the risks attendant to the launch and commercialization of a new product in a competitive market, the availability of capital to fund the Company's continued operations and execute its business plan, and such other factors that are more fully described in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission ("SEC") on March 1, 2022, the Company's Quarterly Report on
Form 10-Q for the quarter ended June 30, 2022, as filed with the SEC on August 9, 2022, and its other filings with the SEC. Statements made in this presentation speak only as of the date of this presentation and should not be relied upon as of any subsequent date, and the Company assumes no obligation to update any such forward- looking statements, whether as a result of new information, future events or otherwise, except as required by law.
2
OUR MISSION
To transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology.
3
CORPORATE OVERVIEW AND MILESTONES
The FIRST and ONLY long-term and implantable CGM System. Available by prescription in US and select markets in Europe. Proven technology with rich development history, regulatory approvals and commercial accomplishments.
2016 - 2017 | 2018 | 2019 | 2020 |
2021
2022
Eversense® | Eversense® |
System (90-day) | System (90-day) |
Eversense® XL | Expanded HCP |
System (180-day) | certification |
to Nurse | |
Practitioners (NPs) | |
and Physician | |
Assistants (PAs) |
NOTE: Items in blue are based on a number of risks and assumptions.
MRI compatibility | NEW Eversense |
Therapeutic | 180-day sensor |
(non-adjunctive) | PMA supplement |
indication | submitted |
Expanded HCP | NEW Eversense |
certification to include | 180-day sensor |
non physicians | submitted |
Achieved 200M | |
Covered Lives | |
Executed | |
Commercial | |
Collaboration | |
Agreement with | |
Ascensia Diabetes | |
Care (ADC) |
Feb. 1 OUS ADC Transition
April 1 US ADC
Transition
Secured 175M in net proceeds
NEW Eversense E3 180-day sensor approval
NEW Eversense E3 180-day sensor approval
365-day Pivotal Trial Initiated
4
HIGH GROWTH MARKET
CGM Fastest Growing Diabetes Technology Segment Globally*
CGM Global Market Size | $8.2 | |||||
~ 37% CAGR | $14B+ | |||||
($) | $7.1 | |||||
Billions | $5.6 | Annual US | ||||
in | Market | |||||
Revenue | $4.3 | |||||
Opportunity | ||||||
$2.7 | ||||||
$1.7 | ||||||
*Estimates for top 4 CGM companies (Dexcom, Abbott, Medtronic and | ||||||
2017 | 2018 | 2019 | 2020 | 2021 | 2022E | Senseonics), based upon available publicly stated guidance, historic |
performance, and external CGM market models. | ||||||
Estimated U.S. CGM Penetration, ~40% US Type 1 & ~25% US IIT | *Company reports, company and analyst estimates. |
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Senseonics Holdings Inc. published this content on 09 September 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 September 2022 14:29:03 UTC.